[1] Wimo A, Guerchet M, Ali G-C, Wu Y-T, Prina AM, Winblad B, et al. The worldwide costs of dementia 2015 and comparisons with 2010. Alzheimer’s Dement 2017;13:1–7. doi:10.1016/j.jalz.2016.07.150.
[2] Cummings JL, Morstorf T, Zhong K. Alzheimer’s disease drug-development pipeline: few candidates, frequent failures. Alzheimers Res Ther 2014;6:37. doi:10.1186/alzrt269.
[3] Kapasi A, DeCarli C, Schneider JA. Impact of multiple pathologies on the threshold for clinically overt dementia. Acta Neuropathol 2017;134:171–86. doi:10.1007/s00401-017-1717-7.
[4] Ransohoff RM. How neuroinflammation contributes to neurodegeneration. Science (80- ) 2016;353:777–83. doi:10.1126/science.aag2590.
[5] Calsolaro V, Edison P. Neuroinflammation in Alzheimer’s disease: Current evidence and future directions. Alzheimer’s Dement 2016;12:719–32. doi:10.1016/j.jalz.2016.02.010.
[6] Heneka MT, Carson MJ, Khoury J El, Landreth GE, Brosseron F, Feinstein DL, et al. Neuroinflammation in Alzheimer’s disease. Lancet Neurol 2015;14:388–405. doi:10.1016/S1474-4422(15)70016-5.
[7] Yeh FL, Hansen D V., Sheng M. TREM2, Microglia, and Neurodegenerative Diseases. Trends Mol Med 2017;23:512–33. doi:10.1016/j.molmed.2017.03.008.
[8] Jones L, Holmans PA, Hamshere ML, Harold D, Moskvina V, Ivanov D, et al. Genetic Evidence Implicates the Immune System and Cholesterol Metabolism in the Aetiology of Alzheimer’s Disease. PLoS One 2010;5:e13950. doi:10.1371/journal.pone.0013950.
[9] Hopperton KE, Mohammad D, Trépanier MO, Giuliano V, Bazinet RP. Markers of microglia in post-mortem brain samples from patients with Alzheimer’s disease: a systematic review. Mol Psychiatry 2018;23:177–98. doi:10.1038/mp.2017.246.
[10] Newcombe EA, Camats-Perna J, Silva ML, Valmas N, Huat TJ, Medeiros R. Inflammation: the link between comorbidities, genetics, and Alzheimer’s disease. J Neuroinflammation 2018;15:276. doi:10.1186/s12974-018-1313-3.
[11] Andersen K, Launer LJ, Ott A, Hoes AW, Breteler MM, Hofman A. Do nonsteroidal anti-inflammatory drugs decrease the risk for Alzheimer’s disease? The Rotterdam Study. Neurology 1995;45:1441–5.
[12] Breitner JC, Welsh KA, Helms MJ, Gaskell PC, Gau BA, Roses AD, et al. Delayed onset of Alzheimer’s disease with nonsteroidal anti-inflammatory and histamine H2 blocking drugs. Neurobiol Aging n.d.;16:523–30.
[13] McGeer PL, Schulzer M, McGeer EG. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer’s disease: a review of 17 epidemiologic studies. Neurology 1996;47:425–32.
[14] Stewart WF, Kawas C, Corrada M, Metter EJ. Risk of Alzheimer’s disease and duration of NSAID use. Neurology 1997;48:626–32.
[15] in ’t Veld BA, Ruitenberg A, Hofman A, Launer LJ, van Duijn CM, Stijnen T, et al. Nonsteroidal Antiinflammatory Drugs and the Risk of Alzheimer’s Disease. N Engl J Med 2001;345:1515–21. doi:10.1056/NEJMoa010178.
[16] Nevado-Holgado AJ, Kim C-H, Winchester L, Gallacher J, Lovestone S. Commonly prescribed drugs associate with cognitive function: a cross-sectional study in UK Biobank. BMJ Open 2016;6:e012177. doi:10.1136/bmjopen-2016-012177.
[17] Wang J, Tan L, Wang H-F, Tan C-C, Meng X-F, Wang C, et al. Anti-Inflammatory Drugs and Risk of Alzheimer’s Disease: An Updated Systematic Review and Meta-Analysis. J Alzheimer’s Dis 2015;44:385–96. doi:10.3233/JAD-141506.
[18] Chen L, Deng H, Cui H, Fang J, Zuo Z, Deng J, et al. Inflammatory responses and inflammation-associated diseases in organs. Oncotarget 2018;9:7204–18. doi:10.18632/oncotarget.23208.
[19] Judge A, Garriga C, Arden NK, Lovestone S, Prieto-Alhambra D, Cooper C, et al. Protective effect of antirheumatic drugs on dementia in rheumatoid arthritis patients. Alzheimer’s Dement Transl Res Clin Interv 2017;3:612–21. doi:10.1016/J.TRCI.2017.10.002.
[20] Oliveira JL, Trifan A, Bastião Silva LA. EMIF Catalogue: A collaborative platform for sharing and reusing biomedical data. Int J Med Inform 2019;126:35–45. doi:10.1016/j.ijmedinf.2019.02.006.
[21] Benjamin O, Lappin SL. Disease Modifying Anti-Rheumatic Drugs (DMARD). StatPearls Publishing; 2019.
[22] Münster T, Furst DE. Pharmacotherapeutic strategies for disease-modifying antirheumatic drug (DMARD) combinations to treat rheumatoid arthritis (RA). Clin Exp Rheumatol n.d.;17:S29-36.
[23] Vlug AE, van der Lei J, Mosseveld BM, van Wijk MA, van der Linden PD, Sturkenboom MC, et al. Postmarketing surveillance based on electronic patient records: the IPCI project. Methods Inf Med 1999;38:339–44.
[24] Grann AF, Erichsen R, Nielsen AG, Frøslev T, Thomsen RW. Existing data sources for clinical epidemiology: The clinical laboratory information system (LABKA) research database at Aarhus University, Denmark. Clin Epidemiol 2011;3:133–8. doi:10.2147/CLEP.S17901.
[25] Bourke A, Dattani H, Robinson M. Feasibility study and methodology to create a quality-evaluated database of primary care data. Inform Prim Care 2004;12:171–7.
[26] Lewis JD, Schinnar R, Bilker WB, Wang X, Strom BL. Validation studies of the health improvement network (THIN) database for pharmacoepidemiology research. Pharmacoepidemiol Drug Saf 2007;16:393–401. doi:10.1002/pds.1335.
[27] García-Gil MDM, Hermosilla E, Prieto-Alhambra D, Fina F, Rosell M, Ramos R, et al. Construction and validation of a scoring system for the selection of high-quality data in a Spanish population primary care database (SIDIAP). Inform Prim Care 2011;19:135–45.
[28] Bolíbar B, Fina Avilés F, Morros R, del Mar Garcia-Gil M, Hermosilla E, Ramos R, et al. Base de datos SIDIAP: la historia clínica informatizada de Atención Primaria como fuente de información para la investigación epidemiológica. Med Clin (Barc) 2012;138:617–21. doi:10.1016/j.medcli.2012.01.020.
[29] Perera G, Pedersen L, Ansel D, Alexander M, Arrighi HM, Avillach P, et al. Dementia prevalence and incidence in a federation of European Electronic Health Record databases: The European Medical Informatics Framework resource. Alzheimer’s Dement 2018;14:130–9. doi:10.1016/j.jalz.2017.06.2270.
[30] Stewart R, Masaki K, Xue Q-L, Peila R, Petrovitch H, White LR, et al. A 32-Year Prospective Study of Change in Body Weight and Incident Dementia. Arch Neurol 2005;62:55. doi:10.1001/archneur.62.1.55.
[31] Semb AG, Kvien TK, Aastveit AH, Jungner I, Pedersen TR, Walldius G, et al. Lipids, myocardial infarction and ischaemic stroke in patients with rheumatoid arthritis in the Apolipoprotein-related Mortality RISk (AMORIS) Study. Ann Rheum Dis 2010;69:1996–2001. doi:10.1136/ard.2009.126128.
[32] Baena-Díez JM, Garcia-Gil M, Comas-Cufí M, Ramos R, Prieto-Alhambra D, Salvador-González B, et al. Association between chronic immune-mediated inflammatory diseases and cardiovascular risk. Heart 2018;104:119–26. doi:10.1136/heartjnl-2017-311279.
[33] Terry M, Therneau M. Package “survival” Title Survival Analysis. 2019.
[34] Friedman B, Cronstein B. Methotrexate mechanism in treatment of rheumatoid arthritis. Jt Bone Spine 2019;86:301–7. doi:10.1016/J.JBSPIN.2018.07.004.
[35] Chan ES, Cronstein BN. Molecular action of methotrexate in inflammatory diseases. Arthritis Res 2002;4:266. doi:10.1186/ar419.
[36] Morabito L, Montesinos MC, Schreibman DM, Balter L, Thompson LF, Resta R, et al. Methotrexate, and Adenosine Release Methotrexate and Sulfasalazine Promote Adenosine Release by a Mechanism that Requires Ecto-5-nucleotidase-mediated Conversion of Adenine Nucleotides. vol. 101. 1998.
[37] Chou M-H, Wang J-Y, Lin C-L, Chung W-S. DMARD use is associated with a higher risk of dementia in patients with rheumatoid arthritis: A propensity score-matched case–control study. Toxicol Appl Pharmacol 2017;334:217–22. doi:10.1016/J.TAAP.2017.09.014.
[38] Kvien TK, Uhlig T, Ødegård S, Heiberg MS. Epidemiological Aspects of Rheumatoid Arthritis: The Sex Ratio. Ann N Y Acad Sci 2006;1069:212–22. doi:10.1196/annals.1351.019.